Last updated on December 2018

A prostate cancer study that will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bone Neoplasm | Urologic Cancer | Metastatic Cancer | Prostate Cancer | Adenocarcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male


Inclusion Criteria:

  • Participants willing to undergo all protocol-specified biopsies Diagnosis of prostate adenocarcinoma as confirmed by the investigator
  • Must have determination of biomarker (BM) status (either BM positive [+] or BM negative [-]) by the sponsor's blood based assay
  • Participants must have measurable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (>=) 10 millimeter (mm) in the long axis or extrapelvic lymph node of >=15 mm in the short axis)
  • Must have previously received at least 1, but no more than 2, lines of novel androgen receptor (AR)-targeted therapy (for example, abiraterone acetate with prednisone, enzalutamide, apalutamide) for prostate cancer.
  • Participants must have had at least 4 weeks of AR-targeted therapy


Exclusion Criteria:

  • Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
  • History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Active malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently remission) less than or equal to (<=) 2 years prior to enrollment
  • Active infection requiring systemic therapy Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.